SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Down 14.7% in December

SCYNEXIS, Inc. (NASDAQ:SCYX) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 678,500 shares, a decline of 14.7% from the November 30th total of 795,400 shares. Based on an average daily volume of 163,900 shares, the short-interest ratio is presently 4.1 days.

SCYNEXIS Trading Up 1.4 %

NASDAQ:SCYX traded up $0.02 during midday trading on Tuesday, hitting $1.09. 315,934 shares of the company were exchanged, compared to its average volume of 189,160. SCYNEXIS has a fifty-two week low of $0.90 and a fifty-two week high of $3.07. The company has a market capitalization of $41.17 million, a PE ratio of -1.47 and a beta of 1.50. The company has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.56.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The company had revenue of $0.66 million for the quarter. As a group, equities research analysts expect that SCYNEXIS will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of SCYNEXIS from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its stake in shares of SCYNEXIS by 28.4% in the 2nd quarter. Acadian Asset Management LLC now owns 540,683 shares of the company’s stock worth $1,080,000 after acquiring an additional 119,600 shares during the period. Geode Capital Management LLC lifted its position in SCYNEXIS by 10.0% in the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after purchasing an additional 36,405 shares during the period. Finally, XTX Topco Ltd purchased a new stake in SCYNEXIS in the 3rd quarter valued at approximately $25,000. 54.37% of the stock is currently owned by hedge funds and other institutional investors.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.